Silodosin CAS 160970-54-7: High-Purity Pharmaceutical Intermediate Manufacturer & Supplier
Discover the critical role of Silodosin in treating benign prostatic hyperplasia. Learn about its synthesis, applications, and why sourcing from a reliable manufacturer is crucial for your pharmaceutical needs.
Get a Quote & SampleProduct Core Value
Silodosin
As a leading supplier in China, we provide high-quality Silodosin (CAS 160970-54-7), a vital pharmaceutical intermediate essential for the symptomatic treatment of benign prostatic hyperplasia (BPH). Our commitment as a manufacturer ensures consistent purity and efficacy, supporting your critical pharmaceutical development and production needs.
- Unlocking targeted relief for BPH: Silodosin's high uroselectivity for alpha (1A) receptors in the prostate, urethra, and bladder trigone minimizes cardiovascular side effects, making it a preferred choice.
- Ensuring therapeutic efficacy through purity: Our Silodosin meets stringent purity standards, crucial for a pharmaceutical intermediate where precise molecular structure dictates patient outcomes.
- Facilitating advanced pharmaceutical synthesis: This compound is a key building block in the synthesis of various medications, contributing to the development of effective treatments for lower urinary tract symptoms.
- Reliable supply chain partner: We offer a stable and dependable source for this essential API, ensuring your production schedules are met with consistent quality.
Key Advantages
High Purity & Quality Assurance
Our Silodosin is manufactured to exacting standards, ensuring 99% purity, a critical factor for its use as a pharmaceutical intermediate and directly impacting the efficacy of BPH treatments.
Specialized Uroselectivity
As a highly selective alpha (1A) adrenergic receptor antagonist, Silodosin provides targeted relief for BPH symptoms by relaxing smooth muscles in the lower urinary tract, a key benefit we deliver.
Consistent Manufacturing Standards
Leveraging advanced synthesis methods, we ensure batch-to-batch consistency and adherence to global pharmaceutical manufacturing guidelines, supporting your production reliability.
Key Applications
API Synthesis
As a crucial pharmaceutical intermediate, Silodosin is fundamental in the synthesis of active pharmaceutical ingredients designed for treating conditions like benign prostatic hyperplasia.
Benign Prostatic Hyperplasia (BPH) Treatment
Silodosin is widely prescribed for the symptomatic relief of BPH, improving urine flow and reducing associated discomfort by acting as a selective alpha-1A blocker.
Urological Health
Its targeted action on receptors in the lower urinary tract makes it invaluable in developing treatments that enhance overall urological health and patient comfort.
Research and Development
The compound serves as a vital tool in ongoing research for novel urological therapies and improvements in drug delivery mechanisms.